Valneva SE (VALN) Cash from Operations (2021 - 2026)
Valneva SE (VALN) posted quarterly Cash from Operations of 355041.73 for Q1 2026, up 95.97% year-on-year from 181174.33 in Q1 2025, and up 98.83% on a QoQ basis from 30243410.67 in Q4 2025.
Valneva SE (VALN) Cash from Operations (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Cash from Operations for 6 consecutive years, with 355041.73 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Operations rose 95.97% year-over-year to 355041.73 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 51742780.71 (up 2.53% YoY) and the FY2025 annual result came in at 60190953.22, up 21.31% from the prior year.
- Cash from Operations rose to 355041.73 in Q1 2026 per VALN's latest filing, from 30243410.67 in the prior quarter.
- Over the last five years, Cash from Operations for VALN reached as high as 73572248532.29 in Q3 2023 and fell as low as 73699730135.43 in Q2 2023.
- A 5-year average of 38055265.92 and a median of 30243410.67 in 2025 frame the typical range for Cash from Operations.
- The largest YoY upside for Cash from Operations was 72726.77% in 2023 against a maximum downside of 89158.54% in 2023.
- Year by year, Cash from Operations stood at 64763253.48 in 2022, then decreased by 17.42% to 76042656.22 in 2023, then surged by 111.92% to 9067219.63 in 2024, then plunged by 433.55% to 30243410.67 in 2025, then surged by 98.83% to 355041.73 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 355041.73, 30243410.67, and 18148094.72 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | -355,041.73 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -355,041.73 |
| Mar 31, 2026 | -355,041.73 |
| Dec 31, 2025 | -30.24 Mn |
| Dec 31, 2025 | -30.24 Mn |
| Sep 30, 2025 | -18.15 Mn |
| Sep 30, 2025 | -18.15 Mn |
| Jun 30, 2025 | -3.00 Mn |
| Jun 30, 2025 | -3.00 Mn |
| Mar 31, 2025 | -8.80 Mn |
| Mar 31, 2025 | -8.80 Mn |
| Dec 31, 2024 | 9.07 Mn |
| Dec 31, 2024 | 9.07 Mn |
| Sep 30, 2024 | -11.42 Mn |
| Sep 30, 2024 | -11.42 Mn |
| Jun 30, 2024 | -41.93 Mn |
| Jun 30, 2024 | -41.93 Mn |
| Mar 31, 2024 | -32.21 Mn |
| Mar 31, 2024 | -32.21 Mn |
| Dec 31, 2023 | -76.04 Mn |
| Dec 31, 2023 | -76.04 Mn |